Lilly, BI resubmit diabetes medication

The companies resubmitted SGLT2 inihibitor empagliflozen for FDA review. The EC approved the drug in May.

June 18, 2014

5:24 pm

Lilly and Boehringer Ingelheim are resubmitting their experimental SGLT2 diabetes medication empagliflozen to the FDA.

“We are very pleased to move forward . . . following a FDA inspection of the Boehringer Ingelheim facility,” BI president and CEO Paul Fonteyne said in a statement Tuesday, referring to the CRL that halted the FDA’s review.

The European Commission greenlighted the diabetes medication, known as Jardiance, in May.

From Our Partners

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.